S&P 500   4,288.39
DOW   33,433.35
QQQ   361.26
Nvidia Stock, Christmas Comes Early If You’re On the Fence
Is Gold Really Boring? (Ad)
Ride the Waves of Wealth With This Oil Tanker 17% Yield
Here’s Why Cloudflare may be the Ultimate Cloud Stock to Own
Is Gold Really Boring? (Ad)
Peloton and Lululemon, Does the Deal Make Sense?
2 Seasonal Stocks to Warm Up Your Portfolio
Is Gold Really Boring? (Ad)
Fed's Powell gets an earful about inflation and interest rates from small businesses
New iPhones Hot In A Bad Way, But Apple Stock Chart is Bullish
S&P 500   4,288.39
DOW   33,433.35
QQQ   361.26
Nvidia Stock, Christmas Comes Early If You’re On the Fence
Is Gold Really Boring? (Ad)
Ride the Waves of Wealth With This Oil Tanker 17% Yield
Here’s Why Cloudflare may be the Ultimate Cloud Stock to Own
Is Gold Really Boring? (Ad)
Peloton and Lululemon, Does the Deal Make Sense?
2 Seasonal Stocks to Warm Up Your Portfolio
Is Gold Really Boring? (Ad)
Fed's Powell gets an earful about inflation and interest rates from small businesses
New iPhones Hot In A Bad Way, But Apple Stock Chart is Bullish
S&P 500   4,288.39
DOW   33,433.35
QQQ   361.26
Nvidia Stock, Christmas Comes Early If You’re On the Fence
Is Gold Really Boring? (Ad)
Ride the Waves of Wealth With This Oil Tanker 17% Yield
Here’s Why Cloudflare may be the Ultimate Cloud Stock to Own
Is Gold Really Boring? (Ad)
Peloton and Lululemon, Does the Deal Make Sense?
2 Seasonal Stocks to Warm Up Your Portfolio
Is Gold Really Boring? (Ad)
Fed's Powell gets an earful about inflation and interest rates from small businesses
New iPhones Hot In A Bad Way, But Apple Stock Chart is Bullish
S&P 500   4,288.39
DOW   33,433.35
QQQ   361.26
Nvidia Stock, Christmas Comes Early If You’re On the Fence
Is Gold Really Boring? (Ad)
Ride the Waves of Wealth With This Oil Tanker 17% Yield
Here’s Why Cloudflare may be the Ultimate Cloud Stock to Own
Is Gold Really Boring? (Ad)
Peloton and Lululemon, Does the Deal Make Sense?
2 Seasonal Stocks to Warm Up Your Portfolio
Is Gold Really Boring? (Ad)
Fed's Powell gets an earful about inflation and interest rates from small businesses
New iPhones Hot In A Bad Way, But Apple Stock Chart is Bullish
OTCMKTS:CHGCY

Chugai Pharmaceutical (CHGCY) Stock Forecast, Price & News

$15.07
-0.32 (-2.08%)
(As of 10/2/2023 ET)
Compare
Today's Range
$14.60
▼
$15.47
50-Day Range
$14.12
▼
$15.50
52-Week Range
$10.99
▼
$15.86
Volume
84,546 shs
Average Volume
64,639 shs
Market Capitalization
$49.57 billion
P/E Ratio
17.12
Dividend Yield
1.33%
Price Target
N/A
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsShort Interest

CHGCY stock logo

About Chugai Pharmaceutical (OTCMKTS:CHGCY) Stock

Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company's products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; Edirol, an Osteoporosis agent; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyroidism; and other diseases comprise Hemlibra, CellCept, Bonviva, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng. It has various development product candidates in the areas of oncology, immunology, neuroscience, hematology, ophthalmology, and other diseases. Chugai Pharmaceutical Co., Ltd. has strategic alliances and collaboration with Roche Group. The company was founded in 1925 and is headquartered in Chuo, Japan. Chugai Pharmaceutical Co., Ltd. operates as a subsidiary of Roche Holding Ltd.

CHGCY Price History

CHGCY Stock News Headlines

September 1, 2023 | investing.com
TOPIX Pharmaceutical (IPHAM.T)
August 19, 2023 | wsj.com
Chugai Pharmaceutical Co. Ltd.
October 3, 2023 | Edge On The Street (Ad)
Is Gold Really Boring?
Many investors perceive gold as a "boring" investment. But according to MoneyWeek, that's a good thing. Gold helps investors sleep soundly as it preserves wealth and creates a hedge against inflation. Today, there's a unique way to invest in gold, with real advantages over coins and mining stocks.
August 3, 2023 | msn.com
Chugai Pharmaceutical (CHGCF) Price Target Decreased by 6.55% to 30.71
April 26, 2023 | markets.businessinsider.com
Here's what to expect from Chugai Pharmaceutical's earnings report
April 18, 2023 | seekingalpha.com
CHGCY Chugai Pharmaceutical Co., Ltd.
March 2, 2023 | msn.com
Chugai, Biofourmis expand team up on digital solutions to measure endometriosis pain
March 2, 2023 | finance.yahoo.com
Chugai and Biofourmis Enter into New Partnership Focused on Data-Driven Virtual Care for Endometriosis-Related Pain
October 3, 2023 | Wall Street Fundamentals (Ad)
The "Plug and Play" Model Putting Online Giants to Shame
While e-commerce has been undergoing a turbulent time, a "simple" model has grown 4X faster than Amazon over the last 3 years. Applying this model to high-margin, recession-resistant businesses has shown to be profitable. But that's just the beginning of explaining the 400+% growth - and potential - of this "diamond in the rough."
December 30, 2022 | seekingalpha.com
Roche: Worthy Of Big Pharma Label, Maybe Not A 'Value Pick' Yet
December 14, 2022 | finance.yahoo.com
Visiox Pharma Announces FDA Acceptance of New Drug Application for Glaucoma
December 12, 2022 | benzinga.com
Short Volatility Alert: Chugai Pharm Co
April 27, 2022 | seekingalpha.com
Chugai Pharmaceutical reports Q1 results
April 25, 2022 | seekingalpha.com
Chugai Pharmaceutical Co., Ltd. 2022 Q1 - Results - Earnings Call Presentation
March 17, 2022 | msn.com
The Daily Biotech Pulse: AbbVie's Rinvoq Gets Label Expansion, AstraZeneca COVID Antibody Cocktail Authorized By UK Regulator, Stealth Touts Positive Data
March 17, 2022 | nasdaq.com
Has Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (CHGCY) Outpaced Other Medical Stocks This Year?
October 14, 2021 | finance.yahoo.com
New Four-year Data Show Sustained Relapse Reduction by Chugai’s Enspryng in People With Neuromyelitis Optica Spectrum Disorder (NMOSD)
July 26, 2021 | seekingalpha.com
Chugai Pharmaceutical Co., Ltd. 2021 Q2 - Results - Earnings Call Presentation
June 28, 2021 | finance.yahoo.com
Chugai’s Enspryng (Satralizumab) Approved by European Commission as First At-home Subcutaneous Treatment for Neuromyelitis Optica Spectrum Disorder (NMOSD)
June 27, 2021 | investing.com
Chugai Pharmaceutical Co Ltd ADR (CHGCY)
April 22, 2021 | seekingalpha.com
Chugai Pharmaceutical Co., Ltd. 2021 Q1 - Results - Earnings Call Presentation
January 12, 2021 | msn.com
Global Markets Remain Mixed Amid China's Rally, Bitcoin Recovers
January 9, 2021 | finance.yahoo.com
Chugai Pharmaceutical Co., Ltd. (CHGCY)
December 9, 2020 | finance.yahoo.com
Chugai’s Enspryng Approved in Taiwan as First Approved Medicine for Neuromyelitis Optica Spectrum Disorder (NMOSD)
October 25, 2020 | seekingalpha.com
Chugai Pharmaceutical Co., Ltd. 2020 Q3 - Results - Earnings Call Presentation
October 21, 2020 | wsj.com
Chugai Pharmaceutical Co. Ltd. ADR
July 21, 2020 | markets.businessinsider.com
Chugai and Biofourmis Partner to Develop an Objective Assessment of Pain Using Digital Technology
See More Headlines
Receive CHGCY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Chugai Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter.

CHGCY Company Calendar

Today
10/03/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Industry
Drugs, proprietaries, & sundries
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCMKTS:CHGCY
CUSIP
N/A
CIK
1453934
Web
www.chugai-pharm.co.jp
Phone
(133) 281-6611
Fax
N/A
Employees
7,664
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
17.12
Forward P/E Ratio
5.52
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
N/A
Quick Ratio
N/A

Sales & Book Value

Annual Sales
$9.65 billion
Price / Sales
5.14
Cash Flow
$0.92 per share
Price / Cash Flow
16.29
Book Value
$3.33 per share
Price / Book
4.52

Miscellaneous

Outstanding Shares
3,289,980,000
Free Float
N/A
Market Cap
$49.57 billion
Optionable
Not Optionable
Beta
0.59
The Best High-Yield Dividend Stocks for 2023 Cover
The Best High-Yield Dividend Stocks for 2023

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

  • Dr. Osamu Okuda (Age 60)
    Pres, CEO & Representative Director
    Comp: $1.22M
  • Mr. Toshiaki Itagaki (Age 63)
    Head of Fin. Supervisory Division, CFO, Exec. VP & Director
  • Toshiya Sasai
    Exec. of Investor Relations Group & Corp. Communications Department
  • Mr. Shinji Hidaka
    Exec. VP and Head of Marketing & Sales Division
  • Mr. Junichi Ebihara
    Exec. VP
  • Dr. Yoshiaki Ohashi (Age 63)
    SVP & Full-time Audit Supervisory Board Member
  • Mr. Tetsuya Yamaguchi
    Exec. VP and Head of Project, Lifecycle Management & Foundation Medicine Unit
  • Mr. Yoshiyuki Yano
    Exec. VP
  • Ms. Satoko Shisai
    Exec. VP & Head of Digital Transformation Unit
  • Dr. Shigehiro Yamada Ph.D. (Age 59)
    Head of Sustainability Department & Full-Time Audit & Supervisory Board Member

Key Competitors

View All Competitors













CHGCY Stock - Frequently Asked Questions

Should I buy or sell Chugai Pharmaceutical stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Chugai Pharmaceutical in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" CHGCY shares.
View CHGCY analyst ratings or view top-rated stocks.

How have CHGCY shares performed in 2023?

Chugai Pharmaceutical's stock was trading at $12.67 at the beginning of the year. Since then, CHGCY shares have increased by 18.9% and is now trading at $15.0675.
View the best growth stocks for 2023 here.

Are investors shorting Chugai Pharmaceutical?

Chugai Pharmaceutical saw a increase in short interest in the month of August. As of August 31st, there was short interest totaling 32,100 shares, an increase of 22.5% from the August 15th total of 26,200 shares. Based on an average trading volume of 143,300 shares, the days-to-cover ratio is currently 0.2 days.
View Chugai Pharmaceutical's Short Interest.

Is Chugai Pharmaceutical a good dividend stock?

Chugai Pharmaceutical (OTCMKTS:CHGCY) pays an annual dividend of $0.20 per share and currently has a dividend yield of 1.27%. The dividend payout ratio is 22.73%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, CHGCY will have a dividend payout ratio of 7.94% next year. This indicates that the company will be able to sustain or increase its dividend.

What is Chugai Pharmaceutical's stock symbol?

Chugai Pharmaceutical trades on the OTCMKTS under the ticker symbol "CHGCY."

How do I buy shares of Chugai Pharmaceutical?

Shares of CHGCY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Chugai Pharmaceutical's stock price today?

One share of CHGCY stock can currently be purchased for approximately $15.07.

How much money does Chugai Pharmaceutical make?

Chugai Pharmaceutical (OTCMKTS:CHGCY) has a market capitalization of $49.57 billion and generates $9.65 billion in revenue each year. The company earns $2.88 billion in net income (profit) each year or $0.88 on an earnings per share basis.

How many employees does Chugai Pharmaceutical have?

The company employs 7,664 workers across the globe.

How can I contact Chugai Pharmaceutical?

Chugai Pharmaceutical's mailing address is 15F, Nihombashi Mitsui Tower, Chuo Ku, Tokyo To 103-8324. The official website for the company is www.chugai-pharm.co.jp. The company can be reached via phone at (133) 281-6611.

This page (OTCMKTS:CHGCY) was last updated on 10/3/2023 by MarketBeat.com Staff

My Account -